ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2894

CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity

Evan Der 1, Ting Zhang 2, Chi Chiu Mok 3, Ramesh Saxena 4, Krishna R. Polu 5, Chandra Mohan 6 and Chaim Putterman7, 1Albert Einstein College of Medicine, New York, 2Biomedical Engineering, University of Houston, Houston, TX, 3Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), 4University of Texas South Western, Dallas, TX, 5Equillium, San Diego, CA, 6University of Houston, Houston, 7Albert Einstein College of Medicine, New York, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus nephritis, systemic lupus erythematosus (SLE) and T cells

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Wednesday, November 13, 2019

Session Title: 6W022: SLE – Etiology & Pathogenesis II (2894–2899)

Session Type: ACR Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in Systemic lupus erythematosus (SLE) patients. However, the pathogenesis of renal disease in lupus patients is not yet fully understood. CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presenting cells (APCs) and various epithelial and endothelial tissues. The CD6/ALCAM pathway plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking, and is central to immune mediated inflammation. The objectives of this research were to study the expression of CD6/ALCAM in kidneys of LN patients, and evaluate the potential of urine ALCAM as a disease biomarker in LN.

Methods: Publicly available single-cell RNA sequencing (scRNA-seq) profiles of clinically indicated renal biopsies obtained from patients with active LN were acquired. scRNA-seq analysis was performed on these datasets using the Seurat package for R. Urine samples were collected from SLE patients of multiple ethnicities and diverse disease activities. ALCAM concentrations were assayed by ELISA then normalized to urine creatinine.

Results: Analysis of biopsies from 19 patients with LN and 11 healthy controls was performed. This analysis confirmed the expression of CD6 exclusively in T cells. ALCAM was expressed in both professional APCs such as macrophages, dendritic cells, and tubular cells. The number of CD6 expressing T cells was elevated in patients with LN compared to healthy controls (p = 0.08) (Figure 1). Patients with class III or IV LN trended towards having more CD6 expressing cells than controls. Furthermore, the number of ALCAM expressing tubular cells and macrophages were elevated in LN compared to healthy controls as well. Urine ALCAM was significantly elevated in patients with active LN when compared with controls across multiple ethnicities. In African American, Hispanic, and Asian patients, urine ALCAM further discriminated active LN from inactive SLE or active SLE patients without LN. Urine ALCAM correlated significantly with SLEDAI, rSLEDAI and PGA in Asian SLE patients (all p< 0.0001) (Figure 2).

Conclusion: Here, we demonstrate increased activity of the CD6/ALCAM pathway within the renal tissues of LN patients. More specifically, infiltrating T cells do indeed express CD6 and the number of CD6 expressing T cells are greater in renal biopsies from patients with LN vs. healthy controls, and in patients with proliferative vs. membranous LN. ALCAM expressing macrophages were also numerically elevated in patients with LN, suggesting increased activation of the CD6/ALCAM signaling pathway in LN. Patients with LN also had elevated levels of ALCAM expressing tubular cells, indicating these resident kidney cells may contribute to signaling and migration of T cells in the context of LN. Finally, urine ALCAM was significantly elevated in active LN patients in multiple ethnicities, and correlated well with clinical disease status, thus representing a promising biomarker for disease evaluation in LN.  These data suggest that a targeted CD6-ALCAM therapy, such as itolizumab, may be a promising for the treatment of LN.

Figure 1. Numbers of CD6 expressing cells in LN -n = 19, red- and healthy control -n = 11, blue- biopsies by single-cell RNA-seq.

Figure 2. A-D: Cr-normalized urine ALCAM was significantly elevated in active LN patients of multiple ethnicities and discriminated patients with diverse disease activities. E-G: Urinary ALCAM correlated well with several clinical parameters including SLEDAI, renal domains of SLEDAI and PGA. HC, healthy controls, ANR, active non-renal lupus; AR, active renal lupus. *, p<0.05; **, p<0.01; ***; p<0.001; ****, p<0.0001.


Disclosure: E. Der, None; T. Zhang, None; C. Mok, None; R. Saxena, None; K. Polu, Equillium, 3; C. Mohan, Equillium, 5, Equillium, Inc, 5; C. Putterman, Equillium, 5, Equillium, Inc, 2, 5, Exagen, 2.

To cite this abstract in AMA style:

Der E, Zhang T, Mok C, Saxena R, Polu K, Mohan C, Putterman C. CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cd6-alcam-signaling-is-upregulated-in-kidneys-with-lupus-nephritis-and-is-associated-with-disease-activity/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd6-alcam-signaling-is-upregulated-in-kidneys-with-lupus-nephritis-and-is-associated-with-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.